OBJECTIVE: We performed a population-based analysis focusing on primary extranodal lymphoma of either testis, kidney, bladder or prostate (PGUL). METHODS: We identified all cases of localized testis, renal, bladder and prostate primary lymphomas (PL) versus primary testis, kidney, bladder and prostate cancers within the Surveillance, Epidemiology, and End Results database (1998-2015). Estimated annual proportion change methodology (EAPC), multivariable logistic regression models, cumulative incidence plots and multivariable competing risks regression models were used. RESULTS: The rates of testis-PL, renal-PL, bladder-PL and prostate-PL were 3.04%, 0.22%, 0.18% and 0.01%, respectively. Patients with PGUL were older and more frequently Caucasian. Annual rates significantly decreased for renal-PL (EAPC: -5.6%; p=0.004) and prostate-PL (EAPC: -3.6%; p=0.03). In multivariable logistic regression models, older ager independently predicted testis-PL (odds ratio [OR]: 16.4; p<0.001) and renal-PL (OR: 3.5; p<0.001), while female gender independently predicted bladder-PL (OR: 5.5; p<0.001). In surgically treated patients, cumulative incidence plots showed significantly higher 10-year cancer-specific mortality (CSM) rates for testis-PL, renal-PL and prostate-PL versus their primary genitourinary tumors. In multivariable competing risks regression models, only testis-PL (hazard ratio [HR]: 16.7; p<0.001) and renal-PL (HR: 2.52; p<0.001) independently predicted higher CSM rates. CONCLUSION: PGUL rates are extremely low and on the decrease in kidney and prostate but stable in testis and bladder. Relative to primary genitourinary tumors, PGUL are associated with worse CSM for testis-PL and renal-PL but not for bladder-PL and prostate-PL, even after adjustment for other-cause mortality.

Cancer Prognostics and Health Outcomes Unit University of Montreal Health Center Montreal Quebec Canada

Department of Urology 2nd Faculty of Medicine Charles University Prag Czech Republic

Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria

Department of Urology European Institute of Oncology Milan Italy

Department of Urology University of Texas Southwestern Dallas TX USA

Department of Urology Weill Cornell Medical College New York NY USA

Division of Experimental Oncology Unit of Urology Urological Research Institute IRCCS San Raffaele Scientific Institute Milan Italy

Division of Urology University of Montreal Hospital Center Montreal Quebec Canada

Institute for Urology and Reproductive Health 1 M Sechenov 1st Moscow State Medical University Moscow Russia

Martini Klinik University Medical Center Hamburg Eppendorf Hamburg Germany

Urology Unit ASST Spedali Civili of Brescia Department of Medical and Surgical Specialties Radiological Science and Public Health University of Brescia Brescia Italy

Vita Salute San Raffaele University Milan Italy

Zobrazit více v PubMed

Non-Hodgkin Lymphoma Cancer stat facts. SEER. https://seer.cancer.gov/statfacts/html/nhl.html

Armitage J.O., Gascoyne R.D., Lunning M.A., Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390:298–310. PubMed

Cheah C.Y., Wirth A., Seymour J.F. Primary testicular lymphoma. Blood. 2014;123:486–493. PubMed

Vannata B., Zucca E. Primary extranodal B-cell lymphoma: current concepts and treatment strategies. Chin Clin Oncol. 2015;4:17. doi: 10.3978/j.issn.2304-3865.2014.12.01. PubMed DOI

Lontos K., Tsagianni A., Msaouel P., Appleman L.J., Nasioudis D. Primary urinary tract lymphoma: rare but aggressive. Anticancer Res. 2017;37:6989–6995. PubMed PMC

Gundrum J.D., Mathiason M.A., Moore D.B., Go R.S. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab. J Clin Oncol. 2009;27:5227–5232. PubMed

Martín O.D., Wadskier L.A., Quiroz Y., Bravo H.P., Cacciamani G., Umaña P. Primary non-Hodgkin lymphoma of the prostate: a case report. Ecancer medical science. 2017;1:789. doi: 10.3332/ecancer.2017.789. PubMed DOI PMC

About the SEER program SEER. https://seer.cancer.gov/about/overview.html

Ruhl J., Adamo M., Dickie L., Negoita S. 2015. Hematopoietic and lymphoid neoplasm coding manual.https://seer.cancer.gov/tools/heme/Hematopoietic_Instructions_and_Rules.pdf

Adamo M., Dickie L., Ruhl J. 2018. SEER program coding and staging manual.https://seer.cancer.gov/manuals/2018/SPCSM_2018_maindoc.pdf

WHO classification of tumours of haematopoietic and lymphoid tissues: International Agency for Research on Cancer. 4th ed. 2008. https://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-Haematopoietic-And-Lymphoid-Tissues-2017

Fay M.P., Tiwari R.C., Feuer E.J., Zou Z. Estimating average annual percent change for disease rates without assuming constant change. Biometrics. 2006;62:847–854. PubMed

Sellman D.P., Simpson W.G., Klaassen Z., Jen R.P., DiBianco J.M., Reinstatler L. Characterization and outcomes of local treatment for primary bladder lymphoma: a population-based cohort analysis. Urol Ann. 2018;10:249–253. PubMed PMC

Groves F.D., Linet M.S., Travis L.B., Devesa S.S. Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000;92:1240–1251. PubMed

Müller A.M.S., Ihorst G., Mertelsmann R., Engelhardt M. Epidemiology of non-Hodgkin’s lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol. 2005;84:1–12. PubMed

Ganeshan D., Iyer R., Devine C., Bhosale P., Paulson E. Imaging of primary and secondary renal lymphoma. AJR Am J Roentgenol. 2013;201:W712–W719. doi: 10.2214/AJR.13.10669. PubMed DOI

Bertolotto M., Derchi L.E., Secil M., Dogra V., Sidhu P.S., Clements R. Grayscale and color Doppler features of testicular lymphoma. J Ultrasound Med. 2015;34:1139–1145. PubMed PMC

Vitolo U., Ferreri A.J.M., Zucca E. Primary testicular lymphoma. Crit Rev Oncol Hematol. 2008;65:183–189. PubMed